MRPL23 and osteosarcoma: Mechanistically, MRPL23-AS1 competed with miR-30b and increased the expression of myosin heavy chain 9 (MYH9), thus activating the Wnt/β-catenin signaling pathway and promoting osteosarcoma progression [4].